Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I, Multi Center, Open Label Study of CC-98633, BCMA Targeted NEX-T Chimeric Antigen Receptor (CAR) T Cells, in Subjects With Relapsed and/or Refractory Multiple Myeloma

NCT04394650 is registered in ClinicalTrials.gov with Juno Therapeutics, a Subsidiary of Celgene as lead sponsor.

NCT NCT04394650
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04394650 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I, Multi Center, Open Label Study of CC-98633, BCMA Targeted NEX-T Chimeric Antigen Receptor (CAR) T Cells, in Subjects With Relapsed and/or Refractory Multiple Myeloma
Lead sponsor
Juno Therapeutics, a Subsidiary of Celgene
Phase
Phase 1
Overall status
Completed
Start date
August 18, 2020
Completion date
July 3, 2024
Enrollment
78 (actual)
Sites
11

Conditions

As the registry lists them; a condition with its own page is linked.

multiple myeloma